checkAd

CellaVision AB Good profitability despite negative COVID-19-effect - Seite 5

Nachrichtenquelle: globenewswire
16.07.2020, 08:20  |  135   |   |   


Zlatko Rihter, VD, CellaVision AB, Tel: 0733-62 11 06,
E-mail: zlatko.rihter@cellavision.se

Magnus Blixt, CFO, CellaVision AB, Tel: 0708-33 81 68
E-mail: magnus.blixt@cellavision.se

About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells products for sample preparation and systems for routine analysis of blood and other body fluids in health care services. The analyzes form an important basis for rapid and correct disease diagnoses, for example in the case of infections and serious cancers. CellaVision's products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 18 local market support organizations covering more than 40 countries. In 2019, sales were SEK 462 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

Publication
This information constitutes information that CellaVision AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 8:20 a.m. CET on July 16, 2020.

Attachment


Seite 5 von 5
Cellavision Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

CellaVision AB Good profitability despite negative COVID-19-effect - Seite 5 The information was submitted for publication at 08.20 CET on July 16, 2020 1 April -30 June 2020 Net sales increased by 5% to SEK 118.0 million (112.4).Sales decreased organically by 15% (+18).EBITDA amounted to SEK 36.2 million (41.3).EBITDA …

Nachrichten des Autors

Titel
Titel
Titel
Titel